baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Kamada Ltd/ IL0010941198 /

2024-04-25 9:20:26 PM	Chg. -0.0100	Volume	Bid9:20:26 PM	Ask9:20:26 PM	High	Low
5.1700USD	-0.19%	7,975 Turnover: 33,504.1000	5.1000Bid Size: 200	5.1700Ask Size: 100	5.2000	5.1200

GlobeNewswire 04-24 Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimil...

GlobeNewswire 04-19 Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 04-16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 04-03 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire 03-22 Alvotech Announces Increase in Number of Own Shares

GlobeNewswire 03-20 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire 03-06 Kamada Issues 2024 CEO Letter to Shareholders

GlobeNewswire 03-06 Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year ...

GlobeNewswire 03-05 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

GlobeNewswire 02-29 Alvotech Appoints Interim Chief Quality Officer

GlobeNewswire 02-28 Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial...

GlobeNewswire 02-26 Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...

GlobeNewswire 02-24 Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...

GlobeNewswire 02-15 Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

GlobeNewswire 01-29 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...

GlobeNewswire 01-19 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

GlobeNewswire 01-10 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

GlobeNewswire 01-03 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...

GlobeNewswire 2023-12-06 Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Dist...

GlobeNewswire 2023-11-29 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...

GlobeNewswire 2023-11-28 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

GlobeNewswire 2023-11-21 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...

GlobeNewswire 2023-11-14 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...

GlobeNewswire 2023-11-13 Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2...

GlobeNewswire 2023-11-10 STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelar...

Kamada Ltd/ IL0010941198 /

If you wish to receive reply to your feedback, please provide your email address.